New Advances in Kawasaki Disease Management: What You Need to Know

Kawasaki Disease is a rare but serious illness predominantly affecting children under five and stands as the primary cause of acquired heart disease in children across the developed world. A new scientific statement published in *Circulation*, the American Heart Association's peer-reviewed journal, outlines substantial advances in cardiac imaging and risk categorization that are improving the diagnosis, treatment, and long-term management of Kawasaki Disease. **Key highlights include:** - _Diagnostic Criteria & Treatment_: Health professionals rely on established symptoms and coronary artery Z-scores to classify risk and evaluate coronary abnormalities. **Early identification** remains crucial to manage potential complications. - _New Risk Scoring_: A novel system in North America incorporates factors like age, race, and inflammation markers to identify high-risk patients. - **Imaging Advances**: Improved echocardiographic techniques enable better detection and management of coronary artery complications. - **Treatment Adjustments**: Intravenous immunoglobulin (IVIG) remains standard, but new dosing strategies for obese patients and additional therapies offer promising results. - **Differentiation from MIS-C**: Overlapping symptoms with Multisystem Inflammatory Syndrome in Children (MIS-C) during COVID-19 prompted new data to help differentiate between the two conditions through additional symptom identification. - **Lifelong Monitoring**: Patients with giant aneurysms need comprehensive care, necessitating specialized heart teams and protocols. The advancements underscore the necessity for consistent monitoring, updated risk categorization, and integrated care plans for patients with Kawasaki Disease, potentially reducing serious cardiovascular complications.